Pharmacokinetic studies in obsessional patients.

Area of Science:

• Pharmacology
• Neuroscience
• Psychiatry

Background:

• Obsessive-compulsive disorder (OCD) is a chronic condition often treated with pharmacotherapy and behavioral interventions.
• Clomipramine is a tricyclic antidepressant effective in managing OCD symptoms.
• Understanding drug and metabolite pharmacokinetics is crucial for optimizing treatment efficacy and safety.

Purpose of the Study:

• To quantify plasma concentrations of clomipramine and its active metabolite, N-desmethylclomipramine, in OCD patients.
• To examine the relationship between clomipramine dosage and steady-state plasma levels.
• To assess the pharmacokinetic profile of clomipramine during chronic administration.

Main Methods:

• A controlled study involving 9 patients with chronic OCD receiving oral clomipramine and behavioral treatment.
• Clomipramine dosage was gradually increased up to 200 mg/day.
• Plasma samples were collected weekly and analyzed for clomipramine and N-desmethylclomipramine using a double radioisotope derivative technique.

Main Results:

• Plasma concentrations of clomipramine and N-desmethylclomipramine increased with dosage during initial treatment weeks.
• Steady-state plasma levels of both compounds were achieved within 7-14 days of consistent daily dosing.
• Higher clomipramine doses resulted in higher steady-state plasma concentrations (e.g., 99 ng/ml at 100 mg/day, 180 ng/ml at 200 mg/day).
• N-desmethylclomipramine plasma levels were approximately double those of clomipramine but did not show a clear dose-relationship.

Conclusions:

• Clomipramine dosage directly influences steady-state plasma concentrations in OCD patients.
• The metabolite N-desmethylclomipramine is present at higher concentrations than the parent drug.
• Pharmacokinetic monitoring may aid in tailoring clomipramine treatment for OCD.